CEOInterviews.AI
Start App
Get an email when Mark Cuban gives a new interview
One email per new interview. Unsubscribe in one click.
Mark Cuban
Co-founder; minority owner, Dallas Mavericks, Cost Plus Drugs

Mark Cuban on Running for President as a Republican: "It Would Be SO Much Fun" | Pivot

📅 Aug 21, 2026 Pivot with Kara Swisher and Scott Galloway 70 MIN 121809 VIEWS 271 SEGMENTS · 2 SPEAKERS
Subscribe to Pivot!    / @pivot   Scott Free August continues, and Kara sits down with Mark Cuban — entrepreneur and co-founder of Cost Plus Drugs. They dig into why prescription drug prices are finally falling, Cuban's war with the healthcare industry, and Costco's surprising Medicare play. Then: why Cuban thinks chips are the new crypto, and California's controversial billionaire tax. Plus — will Cuban actually run for president? 00:00 Intro 00:58 Why RX Prices Are Falling 8:30 What’s Broken in Healthcare 15:57 Costco Gets Into Medicare 22:49 Divesting From Big Health Insurers 25:12 Are Ch...

Questions asked in this interview

12
  1. 4:03So you want to be on the TrumpRx site because you want volume, right?
  2. 7:59What I mean, credit due, deficit, Trump, right?
  3. 15:14Yeah. What has to give then?
  4. 15:50But what do you think of this kind of thing?
  5. 21:50You know, you know what I've been doing around this Paramount deal?
  6. 24:54So what would you... what reaction did you get?
  7. 28:32they're hoping it will go to the sky?
  8. 38:06I think there are five of them. Is that right?
  9. 38:40Oh. Offer over Walter, you mean?
  10. 40:31So where is this all going, these prices of all these sports teams?
  11. 43:10That's cheap. Doesn't it feel cheap?
  12. 1:03:13I mean, the guy who put a target on every Jew in the world's back, right?
Mark Cuban 0:00 ↗
For every single company in this country, if you want to benefit from AI and have it pay for itself, all you have to do is this one thing.
Kara Swisher 0:13 ↗
Hi everyone, this is Pivot from New York Magazine and the Vox Media Podcast Network. I'm Kara Swisher, and once again it is Scott Galloway.
I so never get tired of that. And while Scott continues his August adventures, who the [__] knows where he is, I brought on yet another guest host to make him jealous. This is my goal. It is Mark Cuban, entrepreneur and co-founder of Cost Plus Drugs. He's here. Good to see you, Mark.
Mark Cuban 0:44 ↗
Always good to be seen by you, Kara. It's always a pleasure.
Kara Swisher 0:46 ↗
Yeah, thank you. We've got a lot to get to today. I texted you and said, 'What do you want to talk about?' You said healthcare. Healthcare. Healthcare. So we are going to focus on healthcare, but there's a few other things. But first, let's talk healthcare. Prescription drug prices had their biggest year-over-year drop in more than 60 years. President Trump is taking a victory lap for that. While his TrumpRx site, which is your company Cost Plus Drugs, is partnering with, may be a factor, but experts say a Biden-era policy requiring Medicare to negotiate drug prices is more likely driving costs down.
You got a lot of criticism when this partnership was first announced, not from me. I thought it was actually smart. Talk about it a little bit.
Mark Cuban 1:24 ↗
It's really simple. They refer traffic.
You know, it's just a portal that people can go to, look up prices for 600 drugs.
Kara Swisher 1:34 ↗
Like Obamacare, for example.
Mark Cuban 1:36 ↗
Yeah. Well, a little bit different.
Yeah. I mean, you can go to trumprx.com and you put in the name of the medication, and if they have it, it comes up, and if we're the cheapest, it refers you to us. We've seen our volumes increase, our sales increase, and the good news about that is Republicans want cheaper drugs, independents want cheaper drugs, Democrats. So it's a win. And we've seen our volumes go up, and you know, when our volumes go up, our costs typically go down. And because we're cost plus 15%, we've passed on those savings. So we've literally dropped the price since TrumpRx launched, I think we've dropped the price for over 200 medications. So you know, there's no downside.
Kara Swisher 2:19 ↗
So talk about both of them. This policy from Biden and also what Trump is doing, requiring Medicare to negotiate drug prices at the same time.
Mark Cuban 2:28 ↗
So a couple different things. So with the IRA where you're negotiating for 10 different medications, that's a bonus because along with that, it also put a cap on the amount of out-of-pocket that comes with Medicare Part D to $2,100. And that in turn increased premiums, right? Because the insurance companies had to compensate for the cap that was made available to the patients, which is great for patients. I'm not complaining at all. So it kind of balanced those things out, but there were some drugs where it pushed down the price, and that's always a positive. There's no downside there at all. But I think the bigger issue was that we had biosimilars come out, and that pushed the price of like... explain.
So a biosimilar is like a generic for an injectable drug. Instead of it being a tablet, which should just be called a generic, it is an injectable drug. So like Stelara, Humira, right, things that are injectable. They had the equivalent, a generic version, which is called a biosimilar, and that dropped the price for Stelara from $128,000 a year to, on Cost Plus, it's $365 plus shipping every couple months. Right. For Humira, it went from $8,000 a month to like $400 a month, $450 a month on Cost Plus. And so you saw some really, really expensive, popular drugs drop in price significantly. And I think that drove it more than anything.
Kara Swisher 4:03 ↗
Drove it more than anything. What else has to be done to bring the prices down? So you want to be on the TrumpRx site because you want volume, right? Presumably people using...
Mark Cuban 4:10 ↗
I think he's done a great job on IVF.
Kara Swisher 4:13 ↗
Mm-hmm. Right. Explain that.
Mark Cuban 4:15 ↗
Meaning if you're trying to, you know, build a family and you need the fertility drugs, they were really expensive and he negotiated lower prices. Give him credit for that. You know, he put some pressure on the GLP-1 guys and they came out, and particularly within Medicare, where in certain cases you can get it for $50 a month. So he helped push in that direction. So you know, love them or hate them, and I'm certainly not going to say anything that's going to change anybody's mind, and I'm not going to try, but at the same time, you know, give them credit where credit is due.
Kara Swisher 4:49 ↗
So you got in a lot of trouble when you were arguing with people. You pulled a curse thing. I didn't think you should take that down, honestly. When people were arguing with you, were you surprised by that? Because I think your goal is very clear. You want to lower prescription drug prices.
Mark Cuban 5:03 ↗
Yeah. It's just the people, you know, that's just the way it is. You know, there's two types of TDS. There's Trump derangement syndrome and there's Trump devotion syndrome, right? You know, and they're both equally equal, right? And whatever side of that you're on, that's the button, you know, your buttons that get pushed and the buttons you try to push. But you know, ignore it. Like I said, there's nothing I'm going to say that's going to change anybody's mind about Donald Trump, and I'm certainly not going to try. And when you're thinking about what has to be done next, you can't just put pressure on these people because you have to have other things happen, right? How do you keep that up, the idea of what you're doing? Now, prices did go up during COVID because of the supply chain, etc., etc. What has to happen next on a bigger scale...
Kara Swisher 5:50 ↗
On medication or across the board?
Mark Cuban 5:52 ↗
Across the board. Talk about it across the board. Well, I mean, just generally, there has to be improvements in processes and reduction in prices, and all the inputs are changing, right? And I think the missing piece that's really driving a lot of inflation, you can argue whether it's high or low, is, you know, our deficit, you know, the debt that we're paying a trillion dollars a year on. And you're starting to see that. I don't know what interest rates were doing the last couple days, but you know, the 10-year is up to like 4.6, 4.7, the 30-year over 5.3.
Kara Swisher 6:29 ↗
People are much worried about this. Yeah.
Mark Cuban 6:31 ↗
Right. And so, you know, if you think of it big picture, you always look at the extreme and say what would happen, right? We saw what happens if there's zero interest rates. Everything gets inflated. But let's just say, and this won't happen hopefully, that... well, I'll put it in context. When I graduated from Indiana University, interest rates were 15%. Is there a potential for interest rates to go to 15% again? I don't think so. But if they did, just for sake of example, the price of everything would go up. But more or just as importantly, the price of stocks would go down significantly. The price of assets would go down significantly. 61% of people own stocks directly or indirectly. That's going to change that wealth effect, which I think is holding some people up. Now, there's still that K-shaped economy where people who are struggling are truly struggling and it's going to get worse. But if interest rates go up, it'll get dramatically worse for them. But at the top of the K, it'll get worse for everybody else as well. And that's my big concern because we don't know what that inflection point is. We don't know, is it 6%, is it 8%? Who knows? But we know there is some level where the only people that would get rewarded are savers.
Kara Swisher 7:45 ↗
Savers, right? Exactly. Because they'll get more money. I remember that 15%. I remember it was crazy. It was crazy at the time. At the time it was crazy. 6% was...
Mark Cuban 7:56 ↗
It seemed like... my first mortgage, 12%.
Kara Swisher 7:59 ↗
12%. Mine too. Mine too. You're right. What I mean, credit due, deficit, Trump, right? Like Trump has risen the deficit.
Mark Cuban 8:07 ↗
Everybody. Yeah. Everybody.
Kara Swisher 8:09 ↗
Yeah. Trump, Biden, you name it.
Mark Cuban 8:11 ↗
Trump, I think, gets wins the... I think Scott is...
Well, in terms of aggregate, but it's a lot of big numbers, too. Yeah. Yeah. Right.
Kara Swisher 8:17 ↗
A 5% growth on a bigger number is going to be bigger than a 5% growth.
Mark Cuban 8:21 ↗
Absolutely. But when you think about what has to be done then, so what happens, you know, this has to do with healthcare, of course, is one of the biggest costs for people. We have an economy, a healthcare economy that is driven by just a few companies. You know, they are the middlemen are driving up the cost of everything. You know, not just pharmacy but also medical costs, you name it. There's nothing... they don't contribute much of any value. Yet they increase the cost. They, you know, they make it more miserable for doctors.
Kara Swisher 8:52 ↗
Technical name for these guys. They're...
Mark Cuban 8:54 ↗
Well, there's a bunch of them, right? So, you know, so there's the big healthcare conglomerates, the UnitedHealths, the CVSs, etc. And they have hundreds if not thousands of subsidiaries which include PBMs, which include third-party administrators, which include copay maximizers, all these consultants. There's just so many ways that they get into your pocket and you don't even know it's them. You know, they own clinics, they own, you know, doctors, they hire, you know, 10% either directly or under contract, the number of doctors at the biggest healthcare conglomerate. And so, you know, that creates so much friction and so much cost in the system that we don't even control the cost of our healthcare system anymore.
Kara Swisher 9:46 ↗
No, it's interesting because I think about my own... I have a bunch of prescription drugs and I don't even understand them, and I'm a smart person. Like, I don't understand where the... it's not easy for anybody, and obviously...
Mark Cuban 9:57 ↗
No, that's why we started Cost Plus, right? Because nobody knows the...
Kara Swisher 10:00 ↗
And I thank you for that.
Mark Cuban 10:02 ↗
No problem. costplusdrugs.com. Nobody understands, nobody knows what something costs. Nobody understands why it costs it. Nobody understands why there's a different price for everybody. Nobody understands why there's no transparency other than Cost Plus Drugs, literally. And so if you don't understand these things, it's designed to be confusing. The more information asymmetry, the better leverage they have to raise prices and create friction. And that's exactly what they do. And there's a lot of indirect, not obvious scenarios that are created. So so much work is done to be able to provide the information that they require for each claim, for each medical instance or pharmacy, that you're driving doctors crazy. Not only are you reducing the amount of time they're able to spend with patients, but you're creating burnout to the nth degree. And it wouldn't shock me, you know, if we're starting to see the number of applicants for med school start to decline.
Kara Swisher 11:02 ↗
It's my brother's number one complaint. He's a doctor. Number one complaint. Number one.
Mark Cuban 11:06 ↗
Yeah. It's all the [__] they make you do other than caring for the patient. And it's not necessary. You could extract all that if you just got rid of PBMs. And literally not even get rid of them. If you just made a law that said PBMs are no longer able to control formularies. Formularies are that thing you have to look at with your insurance coverage to see if your drug is covered or not. That gives the PBMs all the leverage to go to all these big brand and specialty drug manufacturers and say, 'Look, if you don't do exactly what we want in paying rebates, doing business or not doing business with Cost Plus Drugs, then we're going to diminish your positioning on the formulary so that you're no longer available to the 80 million people we cover.' And not just for one drug but for your entire portfolio. So that's costing you hundreds of millions or billions. So they have that much control and they do so little, you know, they don't really add much value.
Kara Swisher 12:03 ↗
What do they try to do to your company? What is the biggest challenge?
Mark Cuban 12:07 ↗
Well, they just... they tell these brands, like we have almost every generic other than controlled substances. We don't want to deal with that. Not everything's generic in some critical...
Not everything is. And so then there's brands and branded specialty drugs, and we'll go to the brands and say, look, we have millions of customers, right? We're helping millions and millions of people. Why won't you sell your brands through us? And the answer is always identical: because the PBMs have told us if we deal with costplusdrugs.com, they will diminish us on their formularies. And as I said, it could cost tens of millions, hundreds of millions, billions of dollars across their entire drug portfolio. And they're like, 'Mark, we love you, but we can't cut off our nose to spite our face.' And the reason that they're afraid, that the PBMs are afraid, is because of what we've done to the pricing of biosimilars and specialty generics. Right? When we started publishing the price with our cost, everybody all of a sudden had a reference point with which to negotiate from. Even the FTC, Lina Khan, when she was suing these guys, was using our price list and our markups to define, you know, how much people were getting ripped off and to lead towards a settlement. And, you know, now if all of a sudden you could see what the actual cost is of your Xarelto or whatever it may be and see what the price would be with only a 15% markup, that stabilizes the pricing and revenue for all the PBMs and the insurance companies that own them.
Kara Swisher 13:37 ↗
But you can't publish the prices of the ones you can't get, can you?
Mark Cuban 13:41 ↗
Correct. Right. Well, yeah, because we don't know what our cost is. We can't sell them. And they don't want us to be able to sell them specifically.
Kara Swisher 13:47 ↗
Could you not get those lists, Mark, and start publishing?
Mark Cuban 13:50 ↗
No. No. Literally, it's like Fight Club. Number one rule of Fight Club is you can't talk about Fight Club. Number one rule of PBM contracts and pricing: you can't talk about it. And I'll give you the perfect example.
Kara Swisher 14:01 ↗
You're a clever man. I bet you could get your hands on them.
Mark Cuban 14:04 ↗
It's not that I can't, but it doesn't really help me in terms of pricing, right? Or sell. But let me give you the perfect example. There is something called Tricare, which provides pharmacy to the military people that are enlisted now, people that are retired, wherever they may live, right? And Elizabeth Warren went to them and said, 'Okay, Tricare, you have hired this company, this big PBM called Express Scripts.' Right. So Express Scripts. And so I want to know what you're charging the government every time somebody in the military or formerly in the military uses a drug that you carry. Express Scripts said no. The military said, 'We're not going to show you. That's proprietary information. Get the [__] out of here.' Right. Like you said, you know, you can find it if you need to find it, but President Trump could ask for it. They would say no.
Kara Swisher 15:00 ↗
Ah, wow. So we can't know their prices. They can't know their prices. Interesting.
Mark Cuban 15:05 ↗
They hide them. And that's what they do, not just in this instance, but across the board, right? So we don't know because once we... So we don't know. That's why they're terrified of Cost Plus Drugs.
Kara Swisher 15:14 ↗
Well, what has to give? Yeah. What has to give then?
Mark Cuban 15:17 ↗
Well, I like the, you know, I love the Break Up Big Medicine bill that Josh Hawley and Elizabeth Warren proposed in the Senate, but not one single senator got behind them and co-sponsored it.
Kara Swisher 15:27 ↗
Wow. That's... anyone? Where's it in the House? They even have it in the House?
Mark Cuban 15:32 ↗
No. No one's even brought it up. And I pushed it. You name it. Right. You, anybody, every senator when I saw you right at those events, I talked to all of them.
Kara Swisher 15:41 ↗
What did they say to you? Quietly behind the scenes.
Mark Cuban 15:44 ↗
Quietly behind the back: 'We want their money.'
Kara Swisher 15:46 ↗
Yeah. Yeah. Because they'll...
Mark Cuban 15:48 ↗
We have midterms coming up.
Kara Swisher 15:50 ↗
Yeah. Maybe after the midterms. Will they get any guts? So, another big news in the world of health, I don't know what you think of this. Costco is getting into the Medicare business. The company is teaming up with nonprofit insurer SCAN Group to launch Costco-branded Medicare Advantage plans in two states and Medicare supplement plans in a third. The plans will integrate Costco offerings like prescriptions and over-the-counter drugs plus vision and hearing products. Talk about this. It was really, you know, I'm getting close to Medicare, and although I have insurance, so I don't quite know what I need to do in that regard, but it's so confusing because I have kids and so I want to keep my insurance. But what do you think of this kind of thing?
Mark Cuban 16:27 ↗
It's a sales and marketing effort, right? I mean, I don't know enough about the details to say if it's good or bad. There are some, you know, the thing that people don't realize about Medicare in general: it is driven mostly by private insurance companies.
Kara Swisher 16:40 ↗
It is.
Mark Cuban 16:41 ↗
Medicare Advantage is all private insurance. UnitedHealthcare, in this case, a new one with Costco. You know, Costco does a good job. Hopefully, you know, it'll be an above-board product because not all of them are. Then you have traditional Medicare Part A, Part B, but then you have to buy supplemental insurance because you still, you know, have a 20% hickey that you have to pay for out of pocket for medical, right? And then it doesn't cover your pharmacy. That's Part D. So you use that from a traditional insurance company. So you're getting... you have the same problems even though you're on Medicare.
Kara Swisher 17:15 ↗
Right. Right. People say take A and B, not Advantage and D.
Mark Cuban 17:19 ↗
Yeah. Yeah. And get supplemental insurance, too.
Kara Swisher 17:22 ↗
Right. Right. Exactly. But does this help if a company like Costco is doing this? People have a lot of trust in the company.
Mark Cuban 17:28 ↗
No, it's still the same numbers. The math is still the same math. You can be more efficient and offer incremental benefits. So you might, you know, Costco could offer lower-cost over-the-counter drugs. They can offer lower-cost prescription eyeglasses because it's Costco.
Kara Swisher 17:44 ↗
But it's not the future of healthcare, turning it over to big business.
Mark Cuban 17:47 ↗
No, no, no.
Kara Swisher 17:48 ↗
Yeah. So again, what has to happen is what?
Mark Cuban 17:50 ↗
Well, I mean, so you've got to get rid of the middleman, right? And so what I push for all the time is to get cities and states and companies to let me look at their contracts, because what I do is I've set up my Claude. So I'll just run, and anybody can do this, I run the contracts through Claude and I just tell them where they're getting [__] over.
Kara Swisher 18:14 ↗
Oh.
Mark Cuban 18:15 ↗
And they have no idea. I've literally had some big, big companies do it, talk to me, realize just how badly these PBMs and TPAs, the big Columbus, are ripping them off, and now they're changing to, you know, their pass-through PBMs like Rightway and 360 or SmithRx, and I forget all the names of them. But in any event, so there's alternatives. You don't have to go just with the big guy, and you're doing the country a big disservice. And look, you know tech, right? And so, you know, these guys are trying to do all they can to figure out AI, and it's expensive. The easiest way for any big tech company with more than a thousand employees and families is to look at their healthcare benefits, because every penny they save on their healthcare benefits is cash flow that goes right to the bottom line. And it's just not their core competency. And what happens is their HR departments, particularly in tech, are always undermanned and understaffed. And you know that when somebody has a problem at Vox Media or whoever does your healthcare and benefits, they go right to HR and they complain about having to go through this pre-authorization process, about the claim being denied. And HR spends 90% of their time doing that and doesn't have the resources to look at reducing costs. And when they do see, and I'll walk in the door and meet with them, and huge companies, 'Mark, you're right. We could save millions if not tens of millions of dollars or more, and give us a 20x, that's 200 million, 2 billion, whatever it is in market cap, but we're afraid of our employees because they don't want to change the logo on their card. They want that same insurance card.' So for the one time in all of tech history, they're afraid of their employees. Because the HR people, and all I tell them they have to do is two things: run their contracts, all their healthcare contracts, through Claude or ChatGPT and just say...
Kara Swisher 20:18 ↗
What's the prompt? What's the prompt? How am I getting [__] over?
Mark Cuban 20:21 ↗
Oh, all right. Okay. Is that the technical term? Yeah. Yeah, it really, really is. And it'll tell you because the game they play, the PBMs in particular play, is they mismatch definitions. They'll say this section is for pass-through pricing on drugs. We will pass through all the rebates. Then at the bottom of that paragraph, they'll put in the definitions and they'll say, 'Well, that doesn't include specialty drugs or other fees,'
Kara Swisher 20:49 ↗
Which is all of them.
Mark Cuban 20:50 ↗
And then they get the option of what to make a specialty drug,
Kara Swisher 20:52 ↗
Right? Yeah. Yeah. Yeah.
Mark Cuban 20:54 ↗
It's just... they game the whole thing. And the reason they can do that is these contracts are 50, 100, 200 pages long in some cases. There's no human that has enough coffee available to them to literally go through and drink it. I have gone through and put contracts through where, and these are contracts provided by these huge insurance companies, multi-hundred-billion-dollar companies, right? And they have misspellings. They, you know, this says 36%, this says 46%. And they didn't even catch it, right? It's so mind-numbing.
Kara Swisher 21:26 ↗
Yeah. So you have to think the grifters would be good at...
Mark Cuban 21:30 ↗
Oh, they're brilliant at it, right? Because that's to their favor, right? Well, it's to their benefit. So that's why you need AI. So if you want, for every single company in this country,
Kara Swisher 21:43 ↗
If you want to benefit from AI and have it pay for itself, all you have to do is this one thing,
Mark Cuban 21:49 ↗
To apply it to healthcare.
Kara Swisher 21:50 ↗
Yes. Put your contracts in there. You know, you know what I've been doing around this Paramount deal? I have a friend who's a lawyer who's been putting all the stuff into Claude, and then he sends it to me, and I have to tell you, it's [__] accurate. And then I say something and everyone's like, 'How did she know it would turn out this way?' And I was like, 'This is good, but it matters, the person matters, the prompts, and how you have to be smart.' That it was... it's him and...
Mark Cuban 22:17 ↗
And the prompt, him and the prompt and Claude.
Kara Swisher 22:21 ↗
By itself, you have to be smart enough to know when Claude is wrong.
Mark Cuban 22:24 ↗
That's right. That's right. But I have to tell you, with the combination, it's been startlingly right. But like, it's like using Claude or ChatGPT for healthcare. Yeah.
Kara Swisher 22:34 ↗
Right. It's like, well, you didn't tell me that you had this blood test three years ago, right? So I gave you the wrong answer, so I have to recorrect it.
Mark Cuban 22:43 ↗
Right. Exactly.
Kara Swisher 22:44 ↗
So speaking of healthcare costs, I want to continue and finish on this. You had a post on X the other day that got people talking. You wrote, 'If you own shares in a fund that owns any of the biggest insurance carriers, you're part of the cost of healthcare problem in this country. Those companies put the share price over the health of you, your family, co-workers, and friends. The worst part is that they will lie and mislead you to make more. Tell the funds you own that you will sell if they don't divest their interest in the biggest insurance companies.' That's something else to do. Explain why you're calling this out now. And do you think funds will actually divest?
Mark Cuban 23:15 ↗
So, no, they won't. Some can't just because it's SPX or it's part of an index, right? But they won't because their interest is just in making money, not in doing what's best for the country. And it's the same with the big insurance companies. Their fiduciary responsibility, at least right now, is to shareholders. That's all they care about.
Kara Swisher 23:34 ↗
Yeah. Reminds me of tech companies. But go ahead.
Mark Cuban 23:37 ↗
Yeah. Right. But when you listen to the quarterly earnings conference calls or run them through your favorite LLM, right, and you just say, 'Did they say anything about reducing costs for patients?' The answer is never yes.
Kara Swisher 23:50 ↗
Yeah. Yeah. Yeah. Yeah.
Mark Cuban 23:52 ↗
You know, and if they maybe save something here, they're making it up in fees or somewhere else. They're rarely saying, like, one company, one PBM insurance company said their earnings are going to be a little bit lower for two years because they're making this one adjustment on rebates, but they'll make it up after that and more than compensate and get back to their normal margins. Get the [__] out of here. Like, nobody is going to change their habits that run these companies unless it impacts where they care, and that's the price of the stock.
Kara Swisher 24:26 ↗
Yeah. So does that happen? I mean, it works with South African companies. It works. But this is...
Mark Cuban 24:31 ↗
No, it can when someone, you know, if you had Bernie saying do this, if you had, you know, Jayapal doing this instead of pushing for Medicare for All and just talking trash there, something could happen. If you had Republicans pushing it, it could happen. But again, that's where their money's coming from.
Kara Swisher 24:48 ↗
That's where their money.
Mark Cuban 24:49 ↗
And I'm not saying Bernie and Jayapal aren't getting it, but a lot of people are.
Kara Swisher 24:54 ↗
So what would you... what reaction did you get? They must have been like...
Mark Cuban 24:58 ↗
Not a whole lot, honestly. Just a couple articles and, you know, some requests for quotes, and nobody said, 'Yeah, I did it.' Not one single person.
Kara Swisher 25:05 ↗
Yeah. Yeah. Yeah. I'm going to do it, Mark.
Mark Cuban 25:07 ↗
Thank you.
Kara Swisher 25:08 ↗
I shall do it. I shall do it. Now, yet another post of yours is generating buzz this week. A prediction, one outlet says, has investors watching. You posted, 'Chips as an asset class will be the new crypto.' Explain for me.
Mark Cuban 25:20 ↗
Yeah, I mean, I sold most of my Bitcoin. I went from not being a believer to being a believer, thinking it's a better gold than gold because it's digital. And I also believe that it would be a good hedge against political and geopolitical instability. That it'd be a hedge against, you know, economic instability.
Kara Swisher 25:43 ↗
No. Yeah. Scott got washed out, too, by the way.
Mark Cuban 25:46 ↗
Yeah. Bitcoin has lost the plot.
Kara Swisher 25:48 ↗
Tell me why. Explain.
Mark Cuban 25:50 ↗
Well, all the things I just mentioned had to come true. That's what the maxis were pushing, right? It's protection. Protection against fiat instability. You know, money printer go brr, right? Money printers brring as much as it could possibly brr, right? And the dollar is down. And so you would think the price of Bitcoin in dollars would be skyrocketing, particularly with all this geopolitical instability and all the uncertainty. But it's not. It's, you know, it's flatlined for the most part. Because if there's not a good narrative, like any other stock, right? If the narrative isn't good, supply and demand defines the price unless it pays a dividend, which these don't. And so people aren't buying it. And the reason I said chips are the next thing is because it's not intuitive until you really think about it, right? Chips are like, you know, the Nvidia chips, AMD chips, maybe TPUs from Google and some others. Amazon's trying to make their own, you know, all that stuff.
Kara Swisher 26:51 ↗
Yeah.
Mark Cuban 26:51 ↗
Yeah, Apple is, right? They're like apartments, right? You can rent them, and when they're brand new, they're worth the most. And you might as well rent them out at the highest price, and then over time they degrade in quality because you can't improve them, at least not now. And so I think it makes a good investment, and it makes one that you can create a really cool narrative about. There's so much money chasing it that the crypto bros kind of like these types of things, right? And so narrative makes economic sense. Lots of money there. New crypto.
Kara Swisher 27:30 ↗
How do you make it an asset class then? Just the stocks in it, the stocks of companies that make it?
Mark Cuban 27:35 ↗
Yeah, you can tokenize it. You can use crypto there to tokenize it and sell it as a real-world asset. They can do...
Kara Swisher 27:42 ↗
Tokenize the stocks.
Mark Cuban 27:44 ↗
No, tokenize a chip.
Kara Swisher 27:46 ↗
A chip.
Mark Cuban 27:46 ↗
Yeah, a chip. You know, here's the right to... you own the right. It's like a barrel of oil. You can buy it and sell it, right?
Kara Swisher 27:54 ↗
Oh, like what Michael Saylor was doing, right? Correct. Or not.
Mark Cuban 27:59 ↗
Kind of. Yeah. Yeah. With the Bitcoin itself. That's a lot more complicated. That's more financial engineering, right? But more like you can put contracts on the chips and take the share of revenue created from that chip and sell it.
Kara Swisher 28:16 ↗
Right. Oh, interesting. Are you doing that?
Mark Cuban 28:18 ↗
I'm still trying to learn. There's... I mean, it's relatively new.
Kara Swisher 28:20 ↗
What's the reaction to that?
Mark Cuban 28:22 ↗
I mean, it was like, interesting. Let's see what happens. And the crypto bros that are still holding on: 'You're an idiot. You know, you're dumb.'
Kara Swisher 28:30 ↗
Holder. Holder.
What are they waiting for? What are they actually... they're hoping it will go to the sky?
Mark Cuban 28:37 ↗
There's still a chance it gets hot again, right? Yeah.
Remember, it's supply and demand. I mean, a stock's not a whole lot different than a baseball card. And whatever's hot and whatever has the greatest narrative. So Bitcoin and all the others, Ethereum could go up. I'm really disappointed in Ethereum because it has smart contracts. And my hope when I got excited about it was that we'd be able to use smart contracts and the ledger of Bitcoin to create better social media applications, to create new types of applications that feed data to other things, right? Like tracking the weather so I could buy weather insurance for a Mavs game in case it snows, you know, that type of thing. But it never really came to fruition. And everybody just tried to play the same games: how can I extract the most amount of money from a new blockchain? Because the biggest downfall of crypto always has been the marginal cost to create a competitive blockchain is close to zero. So everybody created their own, said how amazing it was, and you can't have that many.
Kara Swisher 29:40 ↗
Right. Right. Because then it goes, say, like TrumpCoin down to zero, and then you lose all your money at it.
Mark Cuban 29:47 ↗
I know it sounds crazy to say, but a lot of it was a scam, I believe.
Kara Swisher 29:51 ↗
Yeah. I mean, look, when TrumpCoin came out, I again, I'm not... it's not even relevant to Trump. He doesn't have the only memecoin or shitcoin out there. I literally emailed the people I know at Coinbase: 'So what the [__] are you doing putting these shitcoins out when you know all you're going to do is watch people lose their money because it's just a game of musical chairs?' And then, you know, online, if X is like anything, they'll tell you, 'We know it's musical chairs. We know it's not even as good as a lottery ticket, and that's why we play.' Right.
Mark Cuban 30:25 ↗
Right. That's our gambling, and that's our...
Kara Swisher 30:27 ↗
Also, there's also another idiot out there ahead.
Mark Cuban 30:31 ↗
Yeah. Well, that's the whole point, right? Yeah. And so it's just gambling, and that's the rush they get.
Kara Swisher 30:36 ↗
One thing: what can people do with either their prescription drugs? What's the one thing? Is it insurance, not invest in insurance companies? Is it move away from Express Scripts or whatever? What is the one thing people can do to start moving the ball? Because politicians certainly won't.
Mark Cuban 30:54 ↗
It's got to be the CEOs. So self-insured companies provide insurance to 67% of employees who get insurance from work. 67%.

128 more exchanges in this transcript

Sign in free to read the rest of this interview. No card required.

Sign in to read the full transcript

Cite this transcript

APA, MLA, BibTeX
APA

Cuban, M. (2026, August 21). Mark Cuban on Running for President as a Republican: "It Would Be SO Much Fun" | Pivot [Interview transcript]. Pivot with Kara Swisher and Scott Galloway. CEOInterviews.AI. https://ceointerviews.ai/interview/3005652/

MLA

Mark Cuban. "Mark Cuban on Running for President as a Republican: "It Would Be SO Much Fun" | Pivot." Pivot with Kara Swisher and Scott Galloway, 21 Aug. 2026. Transcript, CEOInterviews.AI, https://ceointerviews.ai/interview/3005652/.

BibTeX
@misc{cuban2026_3005652,
  author       = {Mark Cuban},
  title        = {Mark Cuban on Running for President as a Republican: "It Would Be SO Much Fun" | Pivot},
  howpublished = {Interview transcript, Pivot with Kara Swisher and Scott Galloway. CEOInterviews.AI},
  year         = {2026},
  month        = {aug},
  url          = {https://ceointerviews.ai/interview/3005652/},
  note         = {Speaker-attributed transcript with timestamps}
}